Stay updated with breaking news from Danielj Starks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BLB&B Advisors LLC lessened its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 1.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,553 shares of the healthcare product maker’s stock after selling 455 shares during the quarter. BLB&B Advisors LLC’s holdings […]
Genesee Capital Advisors LLC lowered its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 3.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,977 shares of the healthcare product maker’s stock after selling 553 shares during the period. Genesee Capital […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Bridges Investment Management Inc. trimmed its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 0.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 81,462 shares of the healthcare product maker’s stock after selling 339 shares during the period. Bridges Investment Management Inc.’s […]
Abbott Laboratories (NYSE:ABT – Get Free Report) had its price target upped by equities research analysts at Raymond James from $110.00 to $124.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the healthcare product maker’s stock. Raymond James’ target price would suggest a potential […]